Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guided Therapeutics - GTHP -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (64)	5/13/2010 6:09:40 PM
From: caly	Read Replies (1) \| Respond to of 118

Guided Therapeutics Reports First Quarter 2010 Results Current Highlights: - Agreements with Konica Minolta Optical, Inc. to provide approximately $2.34 million in additional commitments to develop new products to detect esophageal and lung cancer based on our non-invasive cancer detection technology platform - Eliminated the majority of our debt and simplified our capital structure by converting debt and preferred stock to common stock and warrants - Removed a lien on our assets - Presented the results of our Food and Drug Administration (FDA) pivotal trial for the LightTouch Cervical Scanner, indicating the technology detected disease up to two years earlier than Pap tests and biopsy, at the American Society of Colposcopy and Cervical Pathology (ASCCP) meeting Press Release Source: Guided Therapeutics, Inc. On Thursday May 13, 2010, 5:36 pm NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (Pink Sheets: GTHP - News) today announced its operating results for the first quarter of 2010. Service revenue for the first quarter of 2010 was $821,000, compared to revenue of $181,000 in the first quarter of 2009. The increase in revenue was primarily due to contracts relating to our core cancer detection technology. The net loss available to common stockholders for the first quarter of 2010 was $3.2 million, or $0.15 per share, compared to a net loss available to common stockholders of $1.4 million, or $0.09 per share, in the comparable quarter of 2009. “We are pleased with the progress we made on a number of fronts in the first quarter of 2010, including simplifying our capital structure and eliminating a lien on our assets, the five presentations to the ASCCP of our clinical results and progress toward completing our FDA premarket approval application,” said Mark L. Faupel, Ph.D., chief executive officer and president of Guided Therapeutics. “We have substantially completed the clinical module of the FDA filing and it is undergoing external review. We are nearing completion of the final module for manufacturing and expect to file both with the FDA during the second quarter of 2010. We also extended our licensing agreement with Konica Minolta, which brings additional revenue to the company and provides a pipeline of products.” “Additionally, the board of directors nominated Dr. Jonathan M. Niloff as a director of the company. We believe that Dr. Niloff will be a key addition to the company because of his clinical background as a Harvard University Ob-GYN and his numerous professional contacts will prove invaluable in the adoption of our technology by the clinical community,” Dr. Faupel said. About Guided Therapeutics Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to provide an objective result at the point of care thereby improving the management of cervical disease. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. GT has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett’s Esophagus using the LightTouch technology platform. For more information, visit GT’s web site www.guidedinc.com.